Metabolism of Omega-3 and Omega-6 During Healthy Aging

Healthy Volunteers Clinical Trial

Official title:

Metabolism of Uniformly Labelled 13C Eicosapentaenoic Acid and 13C Arachidonic Acid During Healthy Aging

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02957188
• Other study ID #: 13C EPA and 13C AA metabolism
• Status: Completed
• Phase: N/A
• First received: October 24, 2016
• Last updated: November 2, 2016
• Start date: August 2015
• Est. completion date: August 2016

Study information

• Verified date: November 2016
• Source: Université de Sherbrooke
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Ethics Review Committee
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine the kinetics of 13C-eicosapentaenoic acid (EPA) and 13C-arachidonic acid (AA) in young and older participants

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: August 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• six young (18-30 y old) and six older (= 70 y old)

• healthy non medicated participants.

Exclusion Criteria:

• Tobacco,

• malnutrition (assessed from blood albumin, haemoglobin and lipids), -

• participants taking an EPA+DHA supplements or consuming more than 2 fish meals per week,

• severe gastro-intestinal problems,

• medication for diabetes,

• thyroid disease,

• renal failure,

• cancer,

• psychiatric difficulties or depression,

• cardiovascular disease,

• glucose intolerance (>8 mmol/L in fasted samples)

• chronic immune condition or inflammation (CRP > 10 mg/l, white cell count),

• recent major surgery or cardiac event,

• dementia,

• ongoing or past severe drug or alcohol abuse,

• ongoing or past intensive physical training.

Study Design

Observational Model: Case-Crossover, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Other:
• 13C eicosapentaenoic acid and 13C arachidonic acid
Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Université de Sherbrooke	Healthy Aging Research Network

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Kinetics of 13C-EPA and 13C-AA		Plasma incorporation of 13C-EPA or 13C-AA was measured from the area under the curve in young and older participants over 28 days post-dose	No